María Natalia Gandur Quiroga: Promising Outcomes for Pazopanib Plus Bevacizumab in Clear Cell RCC

María Natalia Gandur Quiroga posted on X:

“Promising Outcomes for Pazopanib Plus Bevacizumab in Clear Cell RCC: Insights from Phase 2 Study By Dr Hannah Clarke. The combination of pazopanib and bevacizumab in metastatic clear cell renal cell carcinoma (ccRCC) presents significant hope for patients in the favorable risk group. Findings from the Phase 2 trial, presented at the 2024 European Society for Medical Oncology (ESMO) Congress, highlight the efficacy and safety of this novel approach.

Key Highlights:

1.Progression-Free Survival (PFS): Median PFS reached 22.1 months, more than double the historical PFS of 11.1 months seen with pazopanib alone.
2.Clinical Benefit Rate (CBR): An impressive 78% of patients achieved a CBR at 12 months, defined by complete or partial response or stable disease.
3.Objective Response Rate (ORR): ORR was 54.9%, with 43.1% stable disease, translating to an overall 98% clinical benefit.
4.Overall Survival (OS): Median OS stood at 62.9 months, underscoring the potential long-term benefits of the treatment regimen. 5.Safety Profile: Common adverse events included diarrhea (70%), fatigue (69%), and hypertension (54%), while serious adverse events such as hypertension (33%) and liver enzyme elevations (14%) were manageable.

Study Details:

1.Patient Population: The study enrolled 51 treatment-naïve metastatic ccRCC patients, predominantly male (70.6%) with a median age of 65.6 years.
2.Treatment Regimen: Patients received pazopanib 800 mg daily and bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle. 3.Favorable Risk Focus: Due to the availability of immunotherapy for other risk groups, the trial focused on patients within the favorable risk category.

Conclusion:

The results of this trial suggest that alternating pazopanib with bevacizumab could be a viable and effective treatment option for ccRCC patients, particularly those in the favorable risk group.
With the potential for prolonged survival and manageable side effects, this regimen may offer new hope in a space traditionally dominated by immunotherapy.

Additional Findings:

The study reported an impressive CBR response rate at 12 months (40/51 patients), with a follow-up revealing a median PFS of 22.1 months. Notably, this is more than double the median PFS of 11.1 months historically observed with pazopanib alone.
The objective response rate of 54.9% and an overall survival rate of 62.9 months underline the long-term benefit potential for patients treated with this combination therapy.”

Read Further.
Source: María Natalia Gandur Quiroga/X

María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.